- In May 2026, LenioBio GmbH announced a collaboration with Twist Bioscience to integrate LenioBio’s ALiCE® cell-free protein expression platform with Twist’s DNA manufacturing and automation capabilities, aiming to speed up AI-driven protein and antibody design workflows.
- The partnership is designed to shorten the design–build–test cycle by enabling rapid, eukaryotic cell-free expression of complex, full-length proteins, potentially enhancing Twist’s appeal to customers relying on fast, high-quality experimental data.
- We’ll now examine how adding ALiCE® cell-free protein expression could influence Twist Bioscience’s investment narrative and future growth profile.
Uncover the next big thing with 29 elite penny stocks that balance risk and reward.
Twist Bioscience Investment Narrative Recap
To own Twist Bioscience, you need to believe its DNA manufacturing platform can scale into a central toolset for NGS, synthetic biology and AI-driven drug discovery while the company works toward narrowing its losses. The LenioBio collaboration fits that story by tightening the link between design and wet lab validation, but it does not remove the near term execution risk around persistent net losses and the possibility that cash needs could resurface if margin progress stalls.
Among recent announcements, the early access launch of Complex Genes on May 4, 2026 is especially relevant here. Complex Genes broaden Twist’s ability to manufacture hard to make sequences, while ALiCE® adds rapid, eukaryotic cell free protein expression on top of that DNA. Together, they speak directly to one of the key bullish catalysts: that continuous product innovation in difficult biology can support higher value workflows and help justify Twist’s improving gross margin profile.
Yet against this innovation story, investors should still be aware of the risk that ongoing losses and potential future capital needs could...
Read the full narrative on Twist Bioscience (it's free!)
Twist Bioscience's narrative projects $607.3 million revenue and $77.7 million earnings by 2029. This requires 15.8% yearly revenue growth and an earnings increase of about $154 million from -$76.6 million today.
Uncover how Twist Bioscience's forecasts yield a $55.00 fair value, a 10% upside to its current price.
Exploring Other Perspectives
Some of the lowest analysts were already cautious, assuming about US$600.6 million of 2029 revenue and extended losses, so you should weigh whether collaborations like ALiCE® really offset concerns about rising competition and margin pressure or simply highlight how differently reasonable people can view the same stock.
Explore 2 other fair value estimates on Twist Bioscience - why the stock might be worth just $55.00!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Twist Bioscience research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Twist Bioscience research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Twist Bioscience's overall financial health at a glance.
No Opportunity In Twist Bioscience?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com